Typical AI Application Scenarios in Drug Administration
Summary
The National Medical Products Administration published its List of Typical Artificial Intelligence Application Scenarios in Drug Administration on June 18, 2024. The list includes 15 AI application scenarios involved in the access, approval, supervision, risk management, and other considerations for drugs, medical devices and cosmetics. The list aims to promote research and exploration of AI technology in these areas, with a focus on deep integration of AI and drug regulation. It also provides a reference and guidance for drug regulatory authorities, research institutes, tech firms and pharmaceutical companies.
Impacted Sectors
Additional Information
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.